| Government officials had voiced concern about the lack of data on the vaccine's effectiveness in older people, who represented only a small portion of Oxford-AstraZeneca trial participants, though they are high on most countries' vaccination priority lists. The European Medicines Agency said it is not yet known how well the vaccine will work for older people, but "protection is expected, given that an immune response is seen in this age group and based on experience with other vaccines." Britain and India have authorized the vaccine for all adults; the United States is awaiting further evidence from Phase 3 trials. | 
No comments:
Post a Comment